Peptide Dosing Basics for Beginners: BPC-157, TB-500, CJC-1295 & Ipamorelin

Why Dosing Matters in Research

Precision is the foundation of any peptide study. Even small deviations from intended dosing parameters can affect reproducibility, confound results, and complicate interpretation across experimental runs. Getting reconstitution, storage, and administration right is not optional — it is the difference between usable data and a compromised dataset.

This guide covers the basic dosing framework for four of the most-studied peptides in the research literature: BPC-157, TB-500, CJC-1295, and Ipamorelin. Everything here reflects published preclinical research parameters and is intended for institutional researchers operating under approved protocols.

Understanding Peptide Reconstitution

Before any peptide can be administered, it must be reconstituted from its lyophilized (freeze-dried) form into a solution suitable for research use. This step is critical — improper reconstitution is one of the most common sources of dosing error in peptide studies.

Choosing a Reconstitution Solvent

Bacteriostatic water (sterile, preserved with 0.9% benzyl alcohol) is the standard solvent for peptide reconstitution in research contexts. It inhibits bacterial growth in the vial after reconstitution, extending the stability of the solution. View Bacteriostatic Water options ›

Normal saline (0.9% NaCl) is an alternative for some peptides but does not contain antimicrobial preservatives, meaning the reconstituted solution must be used immediately or refrigerated and handled with strict aseptic technique. Bacteriostatic water is preferred in most published research protocols.

Never use tap water, distilled water, or non-sterile solvents. These introduce contamination risk and can compromise peptide stability.

Reconstitution Process

• Swipe the rubber stopper with an alcohol wipe and allow it to dry before piercing.
• Inject the solvent slowly down the inner wall of the vial — not directly onto the lyophilized pellet. This minimizes foaming and shear stress on the peptide molecules.
• Let the vial sit for several minutes after mixing. Do not shake vigorously. Swirl gently until fully dissolved.
• Store reconstituted peptides refrigerated (2–8°C) unless the specific protocol specifies otherwise. Most peptides remain stable for 30–60 days refrigerated after reconstitution.

Concentration Calculation

Calculating the concentration of your reconstituted solution is straightforward:

Concentration (mg/mL) = Peptide weight (mg) ÷ Volume of solvent (mL)

Example: If you reconstitute 10 mg of BPC-157 in 2 mL of bacteriostatic water, your concentration is 5 mg/mL. This means 0.2 mL of solution delivers 1 mg of peptide.

Always document your reconstitution ratio. Inconsistent concentrations are a common source of data variability between experimental groups.

Standard Preclinical Dose Ranges

The following ranges reflect commonly reported parameters from published animal studies. Researchers should consult the specific literature for their study design and model system — doses vary based on animal species, route of administration, study objectives, and institutional protocol requirements.

BPC-157

BPC-157 has been studied across a wide range of doses in rodent models. Common preclinical parameters include:

• Typical dose range: 10–50 mcg/kg body weight
• Frequency: Once or twice daily, depending on protocol
• Administration routes studied: Subcutaneous injection, intraperitoneal injection, topical application (for wound models)

Preclinical research has explored both acute and long-term administration schedules. Some models used daily injections for 2–4 weeks. Researchers should consult the published literature for parameters specific to their research context. View BPC-157 research products › For a full overview of BPC-157's mechanism and research history, see our BPC-157 research guide ›

TB-500 (Thymosin Beta-4)

TB-500 has been studied primarily for its effects on cell migration, tissue repair, and anti-inflammatory response in animal models:

• Typical dose range: 2.5–10 mg per administration in rodent models (scaled to body weight)
• Frequency: Often daily during loading phase, tapering to weekly maintenance in published studies
• Administration routes studied: Subcutaneous injection, local injection at injury site

The loading phase concept — higher and more frequent dosing initially, followed by a lower maintenance schedule — appears in several published study designs. View TB-500 research products › For more on TB-500's mechanism and tissue repair research, see our TB-500 research guide ›

CJC-1295 (GHRH Analogue)

CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue studied for its potential to increase pulsatile GH secretion in research models:

• Typical dose range: 30–60 mcg/kg in published rodent studies
• Frequency: Reported once daily to several times per week depending on protocol
• Administration: Subcutaneous injection is standard in preclinical models

The DAC (Drug Affinity Complex) variant of CJC-1295 has an extended half-life relative to the non-DAC form, which affects dosing frequency. Researchers should confirm which variant they are working with and adjust protocols accordingly.

Ipamorelin (GHRP-2 Analogue)

Ipamorelin is a ghrelin mimetic studied for its selective growth hormone release profile. Research indicates it may produce fewer side effects related to cortisol and prolactin compared to non-selective GHRPs:

• Typical dose range: 10–30 mcg/kg in preclinical models
• Frequency: Often reported 2–3 times daily in published research
• Administration: Subcutaneous injection

Ipamorelin is frequently studied alongside CJC-1295 in combination protocols. When combined, the GH release is additive, and researchers should account for this when designing dosing schedules. View CJC-1295 research products ›

Administration Routes

Subcutaneous Injection

The most common route for peptide administration in preclinical research. A small volume of solution is injected into the subcutaneous layer (fat beneath the skin), typically at the flank or back of the animal. This route offers relatively slow absorption and is well-suited for peptides that require sustained release.

Intraperitoneal Injection

Injection into the peritoneal cavity (body cavity containing the abdominal organs). This route bypasses first-pass hepatic metabolism and is used when rapid systemic distribution is desired. Requires proper technique and training. Institutional protocol requirements for this route are typically more stringent.

Intramuscular Injection

Injection directly into muscle tissue. Used when targeting local tissue response is part of the study design. Absorption is faster than subcutaneous due to greater vascularization of muscle tissue.

Local / Site Injection

Direct injection at the target site (e.g., near a tendon lesion or wound site). Used in studies examining localized tissue repair effects. Particularly common in BPC-157 and TB-500 research.

Topical Application

Applied to the surface of a wound or lesion in gel or solution form. Some studies have explored this route for BPC-157 in wound-healing models. Topical administration is typically limited to surface-level research applications.

Comparing Peptides: Mechanism, Dose, and Purpose

The four peptides covered in this guide operate through different mechanisms and serve distinct research purposes:

*Ranges reflect published preclinical studies in rodent models. Do not extrapolate to human protocols. Always follow your institutional guidelines and approved study parameters.

Peptide Stability and Storage

Proper storage is essential to maintain peptide integrity over the course of a study. Key guidelines:

• Lyophilized peptide: Store at -20°C or below for maximum stability. Most peptides remain stable for 24+ months when properly stored in this form.
• Reconstituted peptide: Store at 2–8°C (refrigerated). Most reconstituted peptides are stable for 30–60 days under refrigeration. Label vials with reconstitution date.
• Avoid repeated freeze-thaw cycles: Each cycle degrades peptide integrity. Aliquot reconstituted solution into smaller vials if multiple freeze-thaw events are a concern.
• Protect from light: Store vials in the original container or in a dark container. Light exposure can degrade certain peptides.
• Verify integrity before use: Check for cloudiness, unusual color, or particulate matter before administration. Any sign of contamination should result in discarding the batch.

Safety Considerations for Research

All peptide research must be conducted under appropriate institutional oversight. Key safety considerations:

• Institutional approval: All animal research protocols must receive IACUC (Institutional Animal Care and Use Committee) or equivalent approval before work begins. For a full overview of regulatory requirements, see our legal guide for research peptides ›
• Personnel training: Anyone administering peptides to research animals must be trained in proper injection technique, aseptic handling, and animal welfare protocols.
• Dosage calculation: Double-check all calculations before preparation. Concentration errors compound over the course of a study.
• Dosage documentation: Record every administration — peptide, dose, route, animal ID, date, and time. Incomplete records undermine data integrity.
• Monitor for adverse effects: Establish observation schedules and report any unexpected clinical signs to the institutional veterinary team.
• Waste disposal: Dispose of all peptide materials, syringes, and vials according to institutional hazardous waste protocols.

BPC-157 + TB-500 Stacking in Research

Researchers frequently examine BPC-157 and TB-500 together in tissue repair models. The theoretical rationale: BPC-157 has been studied primarily for GI protection, tendon-bone repair, and angiogenesis, while TB-500 has been explored for its anti-inflammatory effects and cell migration properties. Some researchers hypothesize these mechanisms may be complementary in musculoskeletal repair studies.

When studying combined administration:

• Use separate vials for each peptide
• Calculate and administer doses independently
• Document the rationale for combined use in your study design
• Be aware that interaction data is limited — this remains an active research question

For combined protocols, browse the full peptide catalog › — all products ship with a Certificate of Analysis verifying purity and identity.

Stacking CJC-1295 + Ipamorelin

The CJC-1295 + Ipamorelin combination is among the most frequently studied peptide pairing in GH-axis research. The rationale: CJC-1295 raises baseline GH levels by stimulating the pituitary, while Ipamorelin adds ghrelin-receptor-mediated pulsatile GH spikes. Together, they may produce a more sustained elevation of GH than either compound alone.

Key considerations for combination research:

• The combined effect on GH levels can be significantly greater than either compound alone
• Some research suggests Ipamorelin is more selective for GH release than other GHRPs, with lower reported effects on cortisol and prolactin
• Dosing schedules must be coordinated — both peptides are typically administered simultaneously in published stacking protocols

The GLOW stack (GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg ›) provides a different combination for researchers studying multi-peptide tissue repair approaches.